Efficacy and Safety of Alitretinoin Therapy in Korean Elderly Patients with Chronic Hand Eczema: A Retrospective Single Center Study
- Author:
Mingyul JO
1
;
Ho Song KANG
;
Min Soo KIM
;
Hyang Joon PARK
;
Mihn Sook JUE
Author Information
- Publication Type:Original Article
- Keywords: Alitretinoin; Efficacy; Elderly; Hand eczema; Korea; Safety
- MeSH: Aged; Blood Cell Count; Chemistry; Eczema; Fasting; Hand; Headache; Humans; Hypertriglyceridemia; Korea; Liver; Retrospective Studies; Thyroid Function Tests; Treatment Outcome
- From:Annals of Dermatology 2019;31(6):595-600
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Chronic hand eczema (CHE) tends to be refractory to conventional therapy. Previous clinical trials have found that alitretinoin is an effective and well-tolerated treatment for CHE. However, there is a relative lack of data on the effectiveness of alitretinoin in elderly patients. OBJECTIVE: The aim of this study was to investigate the efficacy and safety of oral alitretinoin in elderly patients with moderate to severe CHE in Korea. METHODS: We retrospectively investigated 46 CHE patients who were treated with either 10 mg or 30 mg of alitretinoin between June of 2016 and July of 2018. The physician's global assessment (PGA) was used to evaluate treatment efficacy. All adverse events were retrospectively evaluated with respect to laboratory testing, including complete blood cell count, fasting blood chemistry, lipid profile, and liver and thyroid function tests. RESULTS: The mean patient age in this study was 71.0±5.1 years. The treatment period was over eight weeks. A total of 38 of 46 patients (82.6%) exhibited clinical improvement with PGA ratings of ‘clear’ or ‘almost clear.’ There were 13 patients (28.3%) who experienced an adverse effect, with the most common being headache (13.0%) and gastrointestinal symptoms (8.7%) followed by xerosis (6.5%). A total of 13 patients developed or exhibited worsening hypertriglyceridemia (28.3%). CONCLUSION: Alitretinoin can be considered a safe and effective treatment option in elderly patients with moderate to severe CHE.
